172 related articles for article (PubMed ID: 19109042)
1. Predictive factors for the regression of canine transmissible venereal tumor during vincristine therapy.
Scarpelli KC; Valladão ML; Metze K
Vet J; 2010 Mar; 183(3):362-3. PubMed ID: 19109042
[TBL] [Abstract][Full Text] [Related]
2. Canine transmissible venereal tumour: a morphological and immunohistochemical study of 11 tumours in growth phase and during regression after chemotherapy.
Gonzalez CM; Griffey SM; Naydan DK; Flores E; Cepeda R; Cattaneo G; Madewell BR
J Comp Pathol; 2000 May; 122(4):241-8. PubMed ID: 10805977
[TBL] [Abstract][Full Text] [Related]
3. A Clinico-pathological study on the effect of vincristine on transmissible venereal tumour in dogs.
Nak D; Nak Y; Cangul IT; Tuna B
J Vet Med A Physiol Pathol Clin Med; 2005 Sep; 52(7):366-70. PubMed ID: 16109105
[TBL] [Abstract][Full Text] [Related]
4. Vincristine and ivermectin combination chemotherapy in dogs with natural transmissible venereal tumor of different cyto-morphological patterns: A prospective outcome evaluation.
Ferreira Bulhosa L; Estrela-Lima A; da Silva Solcà M; Diniz Gonçalves GS; Larangeira DF; de Pinho FA; Barrouin-Melo SM
Anim Reprod Sci; 2020 May; 216():106358. PubMed ID: 32414469
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic management of transmissible venereal tumors in 30 dogs.
Brown NO; Calvert C; MacEwen EG
J Am Vet Med Assoc; 1980 May; 176(10 Pt 1):983-6. PubMed ID: 7380719
[TBL] [Abstract][Full Text] [Related]
6. Canine transmissible venereal tumor: First report of three clinical cases from Tripoli, Libya.
Hiblu MA; Khabuli NM; Gaja AO
Open Vet J; 2019 Jul; 9(2):103-105. PubMed ID: 31360646
[TBL] [Abstract][Full Text] [Related]
7. Semen quality during vincristine treatment in dogs with transmissible venereal tumor.
Saratsis P; Ypsilantis P; Tselkas K
Theriogenology; 2000 Mar; 53(5):1185-92. PubMed ID: 10798495
[TBL] [Abstract][Full Text] [Related]
8. Vincristine for treatment of transmissible venereal tumor in the dog--.
Calvert CA; Leifer CE; MacEwen EG
J Am Vet Med Assoc; 1982 Jul; 181(2):163-4. PubMed ID: 6749780
[No Abstract] [Full Text] [Related]
9. Transmissible venereal tumor: a retrospective study of 29 cases.
Rogers KS; Walker MA; Dillon HB
J Am Anim Hosp Assoc; 1998; 34(6):463-70. PubMed ID: 9826280
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy using intratumoral bacillus Calmette-Guerin (BCG) and vincristine in dogs with transmissible venereal tumours: therapeutic efficacy and histological changes.
Mukaratirwa S; Chitanga S; Chimatira T; Makuleke C; Sayi ST; Bhebhe E
J S Afr Vet Assoc; 2009 Jun; 80(2):92-6. PubMed ID: 19831270
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour.
Kanca H; Tez G; Bal K; Ozen D; Alcigir E; Atalay Vural S
Vet Med Sci; 2018 Nov; 4(4):364-372. PubMed ID: 30117719
[TBL] [Abstract][Full Text] [Related]
12. Vincristine modulates the expression of Ki67 and apoptosis in naturally occurring canine transmissible venereal tumor (TVT).
Özalp GR; Zik B; Bastan A; Peker S; Özdemir-Salci ES; Bastan I; Darbaz I; Salar S; Karakas K
Biotech Histochem; 2012 Jul; 87(5):325-30. PubMed ID: 22404564
[TBL] [Abstract][Full Text] [Related]
13. Single-drug chemotherapy of canine transmissible venereal tumor with cyclophosphamide, methotrexate, or vincristine.
Amber EI; Henderson RA
J Vet Intern Med; 1992; 6(5):300. PubMed ID: 1432905
[No Abstract] [Full Text] [Related]
14. The role of the multi-drug resistance 1, p53, b cell lymphoma 2, and bcl 2-associated X genes in the biologic behavior and chemotherapeutic resistance of canine transmissible venereal tumors.
Alzate JM; Montoya-Florez LM; Pérez JE; Rocha NS; Pedraza-Ordonez FJ
Vet Clin Pathol; 2019 Dec; 48(4):730-739. PubMed ID: 31777108
[TBL] [Abstract][Full Text] [Related]
15. Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor.
Liu CC; Wang YS; Lin CY; Chuang TF; Liao KW; Chi KH; Chen MF; Chiang HC; Chu RM
Cancer Immunol Immunother; 2008 Apr; 57(4):479-91. PubMed ID: 17710396
[TBL] [Abstract][Full Text] [Related]
16. Does the tumour microenvironment alter tumorigenesis and clinical response in transmissible venereal tumour in dogs?
Ballestero Fêo H; Montoya Flórez L; Yamatogi RS; Prado Duzanski A; Araújo JP; Oliveira RA; Rocha NS
Vet Comp Oncol; 2018 Sep; 16(3):370-378. PubMed ID: 29508538
[TBL] [Abstract][Full Text] [Related]
17. Single-drug chemotherapy of canine transmissible venereal tumor with cyclophosphamide, methotrexate, or vincristine.
Amber EI; Henderson RA; Adeyanju JB; Gyang EO
J Vet Intern Med; 1990; 4(3):144-7. PubMed ID: 2366223
[TBL] [Abstract][Full Text] [Related]
18. Theriogenology question of the month. Transmissible venereal tumor (TVT).
Hasler AH; Weber WT
J Am Vet Med Assoc; 2000 May; 216(10):1557-9. PubMed ID: 10825939
[No Abstract] [Full Text] [Related]
19. Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid.
Pai CC; Kuo TF; Mao SJ; Chuang TF; Lin CS; Chu RM
Vet Immunol Immunopathol; 2011 Feb; 139(2-4):187-99. PubMed ID: 21051091
[TBL] [Abstract][Full Text] [Related]
20. Canine transmissible venereal tumour: a review.
Ganguly B; Das U; Das AK
Vet Comp Oncol; 2016 Mar; 14(1):1-12. PubMed ID: 23981098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
